PDCD1 and hepatocellular carcinoma: This study performed to evaluate the safety and efficacy of interventional therapy (125I seed strand and PVS implantation plus TACE) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) as first-line treatment for HCC patients with Vp4 PVTT.